Unknown

Dataset Information

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk.


ABSTRACT:

SUBMITTER: Hartung HP 

PROVIDER: S-EPMC8609079 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature